Arriagada R et al; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350(4):351-60. Abstract

Aydiner A et al. Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: A phase II study. Lung Cancer. 2007;58(2):246-52. Epub 2007 Aug 1. Abstract

Azzoli CG et al. A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 2007;2(7):638-44. Abstract

Douillard JY et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006;7(9):719-27. Abstract

Felip E et al. Adjuvant chemotherapy in non-small cell lung cancer (NSCLC). Ann Oncol. 2007;18 Suppl 9:ix143-6. Abstract

Fossella F et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21(16):3016-24. Abstract

Gandara DR et al. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S125-7. Abstract

Gridelli C et al. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007;12(7):840-9. Abstract

Horn L, Sandler A. Lung cancer adjuvant therapy. Cancer J. 2007 May-Jun;13(3):210-6. Abstract

Keedy VL, Sandler AB. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci. 2007 Sep 24; [Epub ahead of print. Abstract

Lim KH et al. Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer. Med Oncol. 2007;24(4):388-93. Abstract

Paez JG et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304 (5676):1497-500. Abstract

Pepe C et al. Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10. Proc ASCO2006;Abstract 7009.

Pignon JP et al. Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. Presentation. ASCO 2006;Abstract 7008.

Scagliotti G. Multimodality approach to early-stage non-small cell lung cancer. Lung Cancer. 2007;57 Suppl 2:S6-11. Abstract

Scott WJ et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):234S-242S. Abstract

Stinchcombe TE et al. Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer. J Thorac Oncol. 2007;2(9):819-26. Abstract

Stinchcombe TE et al. Feasibility of adjuvant carboplatin/docetaxel (C/D) in patients (pts) with resected stage I-IIIB non-small cell lung cancer (NSCLC): Preliminary report of a phase II trial. Proc ASCO 2007;Abstract 18069.

Strauss GM et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Presentation. Proc ASCO 2006;Abstract 7007.

Strauss GM et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc ASCO 2004;Abstract 7019.

Syrigos KN et al. Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. Anticancer Res. 2007;27(4C):2887-92. Abstract

Tomizawa Y et al. A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer. Am J Clin Oncol. 2007;30(5):498-502. Abstract

Winton T et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2589-97. Abstract

Winton TL et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR. 10. Proc ASCO 2004;Abstract 7018.